| Management of hepatotoxicity related to immune checkpoint inhibitors treatment |
| Received:March 14, 2020 Revised:April 08, 2020 Click here to download the full text |
| Citation of this paper:HUANG Pei-xin,ZHANG Lan,CHEN Yi.Management of hepatotoxicity related to immune checkpoint inhibitors treatment[J].Chinese Journal of Clinical Medicine,2020,27(6):926-930 |
| Hits: 1527 |
| Download times: 674 |
| Author Name | Affiliation | E-mail | | HUANG Pei-xin | Department of Hepatic Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | ZHANG Lan | Department of Hepatic Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | CHEN Yi | Department of Hepatic Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | chen.yi1@zs-hospital.sh.cn |
|
| Abstract:Immune checkpoint inhibitors (ICIs) have shown remarkable effect in the treatment of malignant tumor, which has opened a new era of tumor immunotherapy. However, with the wide application of ICIs, non-specific immune activation due to the drugs brought a series of immune-related adverse events (irAEs). Liver is a vital organ of drug metabolism and digestion. Therefore, immune-related hepatotoxicity should be concerned by clinicians. Early detection, early diagnosis, and standard treatment are the key points to improve the prognosis. Here, this review briefly described the incidence and possible mechanism of irAEs, and summarized the present management of immune-related hepatotoxicity. |
| keywords:immune checkpoint inhibitors immune-related adverse events hepatotoxicity |
| HTML View Full Text View/Add Comment Download reader |
|
|
|